Genizon granted Genentech an exclusive license to its GeneMap of diasease-associated genes generated from a whole-genome association study of Crohn’s disease. According to the Genizon, this study was conducted in 500 families from the Quebec Founder Population, which because of its genetic homogeneity, is believed to be among the best populations worldwide for genetic research.

Under the terms of the agreement, Genizon will receive an upfront payment, research funding, and milestone payments for each therapeutic product that may emerge from the collaboration.

Previous articleFDA Forms Internal Nanotechnology Task Force
Next articleImclone Decides to Go It Alone